These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 1371177)

  • 21. Nevirapine synergistically inhibits HIV-1 replication in combination with zidovudine, interferon or CD4 immunoadhesin.
    Koup RA; Brewster F; Grob P; Sullivan JL
    AIDS; 1993 Sep; 7(9):1181-4. PubMed ID: 7692883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human immunodeficiency virus 1 (HIV-1)-specific reverse transcriptase (RT) inhibitors may suppress the replication of specific drug-resistant (E138K)RT HIV-1 mutants or select for highly resistant (Y181C-->C181I)RT HIV-1 mutants.
    Balzarini J; Karlsson A; Sardana VV; Emini EA; Camarasa MJ; De Clercq E
    Proc Natl Acad Sci U S A; 1994 Jul; 91(14):6599-603. PubMed ID: 7517553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitors.
    Condra JH; Emini EA; Gotlib L; Graham DJ; Schlabach AJ; Wolfgang JA; Colonno RJ; Sardana VV
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1441-6. PubMed ID: 1380789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 3. Dipyrido[2,3-b:2',3'-e]diazepinones.
    Proudfoot JR; Patel UR; Kapadia SR; Hargrave KD
    J Med Chem; 1995 Apr; 38(8):1406-10. PubMed ID: 7537334
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel 2-chloro-8-arylthiomethyldipyridodiazepinone derivatives with activity against HIV-1 reverse transcriptase.
    Khunnawutmanotham N; Chimnoi N; Saparpakorn P; Pungpo P; Louisirirotchanakul S; Hannongbua S; Techasakul S
    Molecules; 2007 Feb; 12(2):218-30. PubMed ID: 17846572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pyrido [1,2a] indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
    Taylor DL; Ahmed PS; Chambers P; Tyms AS; Bedard J; Duchaine J; Falardeau G; Lavallée JF; Brown W; Rando RF; Bowlin T
    Antivir Chem Chemother; 1999 Mar; 10(2):79-86. PubMed ID: 10335402
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical experience with non-nucleoside reverse transcriptase inhibitors: L-697,661 and nevirapine.
    Kilby JM; Saag MS
    Adv Exp Med Biol; 1996; 394():291-8. PubMed ID: 8815693
    [No Abstract]   [Full Text] [Related]  

  • 28. Enzymatic properties of two mutants of reverse transcriptase of human immunodeficiency virus type 1 (tyrosine 181-->isoleucine and tyrosine 188-->leucine), resistant to nonnucleoside inhibitors.
    Loya S; Bakhanashvili M; Tal R; Hughes SH; Boyer PL; Hizi A
    AIDS Res Hum Retroviruses; 1994 Aug; 10(8):939-46. PubMed ID: 7529032
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lamivudine resistance of HIV type 1 does not delay development of resistance to nonnucleoside HIV type 1-specific reverse transcriptase inhibitors as compared with wild-type HIV type 1.
    Jonckheere H; Witvrouw M; De Clercq E; Anné J
    AIDS Res Hum Retroviruses; 1998 Feb; 14(3):249-53. PubMed ID: 9491915
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. 4. 2-Substituted dipyridodiazepinones as potent inhibitors of both wild-type and cysteine-181 HIV-1 reverse transcriptase enzymes.
    Proudfoot JR; Hargrave KD; Kapadia SR; Patel UR; Grozinger KG; McNeil DW; Cullen E; Cardozo M; Tong L; Kelly TA
    J Med Chem; 1995 Nov; 38(24):4830-8. PubMed ID: 7490732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro.
    Larder BA; Kellam P; Kemp SD
    Nature; 1993 Sep; 365(6445):451-3. PubMed ID: 7692302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Highly specific inhibitors of human immunodeficiency virus type I that are particularly targeted at the reverse transcriptase].
    de Clercq E; Snoeck R
    Pathol Biol (Paris); 1993 Mar; 41(3):230-6. PubMed ID: 7687340
    [No Abstract]   [Full Text] [Related]  

  • 33. Structure-based design of non-nucleoside reverse transcriptase inhibitors of drug-resistant human immunodeficiency virus.
    Mao C; Sudbeck EA; Venkatachalam TK; Uckun FM
    Antivir Chem Chemother; 1999 Sep; 10(5):233-40. PubMed ID: 10574178
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sensitivity and resistance to (+)-calanolide A of wild-type and mutated forms of HIV-1 reverse transcriptase.
    Quan Y; Motakis D; Buckheit R; Xu ZQ; Flavin MT; Parniak MA; Wainberg MA
    Antivir Ther; 1999; 4(4):203-9. PubMed ID: 10723499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of nonnucleoside HIV reverse transcriptase inhibitors.
    Tucker TJ; Lumma WC; Culberson JC
    Methods Enzymol; 1996; 275():440-72. PubMed ID: 9026654
    [No Abstract]   [Full Text] [Related]  

  • 36. Quantitative analysis of the endogenous reverse transcriptase reactions of HIV type 1 variants with decreased susceptibility to azidothymidine and nevirapine.
    Krogstad P; Chen IS; Canon J; Rey O
    AIDS Res Hum Retroviruses; 1996 Jul; 12(11):977-83. PubMed ID: 8827213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of a human immunodeficiency virus-1 in vitro DNA synthesis system to study reverse transcriptase inhibitors.
    Borroto-Esoda K; Boone LR
    Antiviral Res; 1994 Apr; 23(3-4):235-49. PubMed ID: 7519003
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. 5. 4-Substituted and 2,4-disubstituted analogs of nevirapine.
    Kelly TA; Proudfoot JR; McNeil DW; Patel UR; David E; Hargrave KD; Grob PM; Cardozo M; Agarwal A; Adams J
    J Med Chem; 1995 Nov; 38(24):4839-47. PubMed ID: 7490733
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.
    Chow YK; Hirsch MS; Merrill DP; Bechtel LJ; Eron JJ; Kaplan JC; D'Aquila RT
    Nature; 1993 Feb; 361(6413):650-4. PubMed ID: 7679778
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro anti-HIV-1 synergy between non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz.
    Kollmann C; Tremblay C; Giguel F; Chou TC; Hirsch MS
    Antivir Ther; 2001 Jun; 6(2):143-4. PubMed ID: 11491419
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.